Claris Lifesciences has received approval from the Ministry of Health (MoH), Russia, to market two more anti-infectives, namely Fluconazole IV 100 ml. and Levofloxacin IV 100 ml.
Fluconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections, whereas Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections. With the total pharmaceutical market size estimated at $11.2 billion and estimated to grow at 12-15 per cent CAGR, Russia is one of the largest and fastest growing pharmaceutical markets in the world. The generic market size in Russia is estimated to be at $3.5 billion.
With these two new approvals, Claris now has a basket of four major anti-infective products for Russia, including existing approved products, namely, Ciprofloxacin IV and Metronidazole IV. The total market size of these four parental products is estimated to be $53 million.
| Company Name | CMP |
|---|---|
| Redington | 234.90 |
| Adani Enterprises | 2218.35 |
| Amrapali Industries | 17.53 |
| Rashi Peripheral | 455.25 |
| PDS | 301.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: